Group of Twenty

The Group of 20 is comprised of the 19 leading industrialised and emerging economies plus the European Union (EU). The G20 accounts for three quarters of global trade and two thirds of the global population. Its members are: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, South Africa, South Korea, Turkey, the United Kingdom, the USA and the EU.

The agenda of the G20 includes the discussion of topics central to international economic and monetary policy. Originally, the meetings did only focus on these topics. In the meantime, however, the agenda has evolved and additional topics are discussed and addressed in detail. As a result, the heads of state and government as well as certain ministers also held meetings. The country that holds the presidency defines the thematic focus.

When Germany held the Presidency in 2017, it welcomed the other countries with the motto “shaping an interconnected world”. Germany made Global Health a priority of its presidency.

In fact, the first ever meeting of G20 health ministers took place on the 19 and 20 May 2017 in Berlin. The two-day meeting entitled "Together Today for a Healthy Tomorrow - Joint Commitment for Shaping Global Health" centred on the control of global health threats. To better prepare for health crises in the future, at their meeting with representatives of the World Health Organization (WHO) and the World Bank, the G20 Health Ministers simulated the contingency of a transnational disease outbreak. Moreover, the meeting saw the adoption of the “Berlin Declaration of the G20 Health Ministers”.

The discussions of the G20 Ministers focused on the improvement of health crisis management, the strengthening of health care systems and the control of antimicrobial resistance.

Health minister statements since 2017

Ever since Germany’s G20 Presidency in 2017, global health has been high on the G20 agenda.  In this context, the control of dangerous pathogens, whose relevance was starkly highlighted during the Ebola and COVID-19 crises, is high on the agenda. Other priorities include the prudent use of antibiotics and improved research and development of new antibiotics.